Morady F, Scheinman M M, Desai J
Ann Intern Med. 1982 Mar;96(3):337-43. doi: 10.7326/0003-4819-96-3-337.
Since disopyramide was introduced 5 years ago, the therapeutic spectrum of this drug in treating patients with ventricular and atrial arrhythmias has been found to be similar to that of the other type I antiarrhythmic drugs, quinidine and procainamide. Disopyramide has the potential to suppress sinus node function and, therefore, must be used cautiously in patients with the sick sinus syndrome. The available data indicate that it can be used safely in patients with bundle branch block and first-degree or type I second-degree atrioventricular block. Disopyramide has been found at times to precipitate ventricular tachycardia or ventricular fibrillation. Because this drug often causes decompensation in patients with congestive heart failure, it must be used very cautiously, if at all, in such patients.
自从5年前丙吡胺被引入以来,已发现该药在治疗室性和房性心律失常患者方面的治疗谱与其他I类抗心律失常药物奎尼丁和普鲁卡因胺相似。丙吡胺有抑制窦房结功能的潜在作用,因此,病态窦房结综合征患者必须谨慎使用。现有数据表明,它可安全用于束支传导阻滞和一度或I型二度房室传导阻滞患者。丙吡胺有时会诱发室性心动过速或心室颤动。由于该药常导致充血性心力衰竭患者失代偿,因此,此类患者必须极其谨慎地使用(如果使用的话)。